Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer

Tomohisa Egawa, Tetsuro Kubota, Atsushi Nagashima, Masakazu Doi, Mitsuhide Kitano, Shinobu Hayashi, Hiroshi Yoshii, Yoshiro Saikawa, Masaki Kitajima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We report herein the efficacy and feasibility of weekly administration of paclitaxel for advanced/recurrent gastric cancer retrospectively. Eleven patients with advanced or recurrent gastric cancer who had received prior chemotherapy were treated with this regimen. Seventy mg of paclitaxel per m2 dissolved in 250 ml 5% glucose was administered by 1-hour intravenous infusion once a week for 3 weeks followed by 1 week rest. To avoid hypersensitivity reactions, the following short premedication was given to all the patients 1 hour before paclitaxel treatment: Dexamethasone 20 mg intravenously (i.v.), diphenhydramine 50 mg i.v., and ranitidine 50 mg i.v. Treatment cycle was 1 to 23 with an average cycle of 5.4. The response rate was 33% (2/6 with measurable lesions), the median time to progression was 104 days, and the median survival time was 160 days. Grade 3 neutropenia occurred in 27.2% of the patients. Weekly paclitaxel may be a promising regimen as a second-line chemotherapy for advanced/recurrent gastric cancer. However, special attention needs to be paid to the neutropenic adverse effect in gastric cancer patients with poor performance status than 2 (greater).

Original languageEnglish
Pages (from-to)877-881
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume31
Issue number6
Publication statusPublished - 2004 Jun

Fingerprint

Paclitaxel
Stomach Neoplasms
Diphenhydramine
Drug Therapy
Ranitidine
Premedication
Neutropenia
Intravenous Infusions
Dexamethasone
Hypersensitivity
Glucose
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Egawa, T., Kubota, T., Nagashima, A., Doi, M., Kitano, M., Hayashi, S., ... Kitajima, M. (2004). Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 31(6), 877-881.

Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer. / Egawa, Tomohisa; Kubota, Tetsuro; Nagashima, Atsushi; Doi, Masakazu; Kitano, Mitsuhide; Hayashi, Shinobu; Yoshii, Hiroshi; Saikawa, Yoshiro; Kitajima, Masaki.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 31, No. 6, 06.2004, p. 877-881.

Research output: Contribution to journalArticle

Egawa, T, Kubota, T, Nagashima, A, Doi, M, Kitano, M, Hayashi, S, Yoshii, H, Saikawa, Y & Kitajima, M 2004, 'Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 31, no. 6, pp. 877-881.
Egawa T, Kubota T, Nagashima A, Doi M, Kitano M, Hayashi S et al. Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer. Gan to kagaku ryoho. Cancer & chemotherapy. 2004 Jun;31(6):877-881.
Egawa, Tomohisa ; Kubota, Tetsuro ; Nagashima, Atsushi ; Doi, Masakazu ; Kitano, Mitsuhide ; Hayashi, Shinobu ; Yoshii, Hiroshi ; Saikawa, Yoshiro ; Kitajima, Masaki. / Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2004 ; Vol. 31, No. 6. pp. 877-881.
@article{9e1c5fca87a64ab791efeaba2af7c5e8,
title = "Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer",
abstract = "We report herein the efficacy and feasibility of weekly administration of paclitaxel for advanced/recurrent gastric cancer retrospectively. Eleven patients with advanced or recurrent gastric cancer who had received prior chemotherapy were treated with this regimen. Seventy mg of paclitaxel per m2 dissolved in 250 ml 5{\%} glucose was administered by 1-hour intravenous infusion once a week for 3 weeks followed by 1 week rest. To avoid hypersensitivity reactions, the following short premedication was given to all the patients 1 hour before paclitaxel treatment: Dexamethasone 20 mg intravenously (i.v.), diphenhydramine 50 mg i.v., and ranitidine 50 mg i.v. Treatment cycle was 1 to 23 with an average cycle of 5.4. The response rate was 33{\%} (2/6 with measurable lesions), the median time to progression was 104 days, and the median survival time was 160 days. Grade 3 neutropenia occurred in 27.2{\%} of the patients. Weekly paclitaxel may be a promising regimen as a second-line chemotherapy for advanced/recurrent gastric cancer. However, special attention needs to be paid to the neutropenic adverse effect in gastric cancer patients with poor performance status than 2 (greater).",
author = "Tomohisa Egawa and Tetsuro Kubota and Atsushi Nagashima and Masakazu Doi and Mitsuhide Kitano and Shinobu Hayashi and Hiroshi Yoshii and Yoshiro Saikawa and Masaki Kitajima",
year = "2004",
month = "6",
language = "English",
volume = "31",
pages = "877--881",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "6",

}

TY - JOUR

T1 - Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer

AU - Egawa, Tomohisa

AU - Kubota, Tetsuro

AU - Nagashima, Atsushi

AU - Doi, Masakazu

AU - Kitano, Mitsuhide

AU - Hayashi, Shinobu

AU - Yoshii, Hiroshi

AU - Saikawa, Yoshiro

AU - Kitajima, Masaki

PY - 2004/6

Y1 - 2004/6

N2 - We report herein the efficacy and feasibility of weekly administration of paclitaxel for advanced/recurrent gastric cancer retrospectively. Eleven patients with advanced or recurrent gastric cancer who had received prior chemotherapy were treated with this regimen. Seventy mg of paclitaxel per m2 dissolved in 250 ml 5% glucose was administered by 1-hour intravenous infusion once a week for 3 weeks followed by 1 week rest. To avoid hypersensitivity reactions, the following short premedication was given to all the patients 1 hour before paclitaxel treatment: Dexamethasone 20 mg intravenously (i.v.), diphenhydramine 50 mg i.v., and ranitidine 50 mg i.v. Treatment cycle was 1 to 23 with an average cycle of 5.4. The response rate was 33% (2/6 with measurable lesions), the median time to progression was 104 days, and the median survival time was 160 days. Grade 3 neutropenia occurred in 27.2% of the patients. Weekly paclitaxel may be a promising regimen as a second-line chemotherapy for advanced/recurrent gastric cancer. However, special attention needs to be paid to the neutropenic adverse effect in gastric cancer patients with poor performance status than 2 (greater).

AB - We report herein the efficacy and feasibility of weekly administration of paclitaxel for advanced/recurrent gastric cancer retrospectively. Eleven patients with advanced or recurrent gastric cancer who had received prior chemotherapy were treated with this regimen. Seventy mg of paclitaxel per m2 dissolved in 250 ml 5% glucose was administered by 1-hour intravenous infusion once a week for 3 weeks followed by 1 week rest. To avoid hypersensitivity reactions, the following short premedication was given to all the patients 1 hour before paclitaxel treatment: Dexamethasone 20 mg intravenously (i.v.), diphenhydramine 50 mg i.v., and ranitidine 50 mg i.v. Treatment cycle was 1 to 23 with an average cycle of 5.4. The response rate was 33% (2/6 with measurable lesions), the median time to progression was 104 days, and the median survival time was 160 days. Grade 3 neutropenia occurred in 27.2% of the patients. Weekly paclitaxel may be a promising regimen as a second-line chemotherapy for advanced/recurrent gastric cancer. However, special attention needs to be paid to the neutropenic adverse effect in gastric cancer patients with poor performance status than 2 (greater).

UR - http://www.scopus.com/inward/record.url?scp=3042667677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042667677&partnerID=8YFLogxK

M3 - Article

C2 - 15222104

AN - SCOPUS:3042667677

VL - 31

SP - 877

EP - 881

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 6

ER -